Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Altamira TherapeuticsFRA:2QA 30 3-1 Month Momentum % is N/A% as of Sep. 13, 2026. GuruFocus rates FRA:2QA with a GF Score™ of 30/100. The stock has 4 warning signs investors should review. Among 1,378 Biotechnology companies, Altamira Therapeutics ranks worse than 73.58% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-13), Altamira Therapeutics's 3-1 Month Momentum % is N/A%.
The industry rank for Altamira Therapeutics's 3-1 Month Momentum % or its related term are showing as below:
FRA:2QA's 3-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: 1.51 * Ranked among companies with meaningful 3-1 Month Momentum % only.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Altamira Therapeutics 3-1 Month Momentum % Related Terms
FRA:2QA vs CPMV, LYRA, RGBP: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Altamira Therapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Altamira Therapeutics 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Altamira Therapeutics's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Altamira Therapeutics's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Altamira Therapeutics (FRA:2QA) has a 3-1 Month Momentum % of N/A% as of Sep. 13, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Altamira Therapeutics and its competitors. According to the industry distribution chart, Altamira Therapeutics ranks #1014 out of 1378 companies in the Biotechnology industry, placing it in the top 73.6%.
Is Altamira Therapeutics' 3-1 Month Momentum % too high?
Altamira Therapeutics' current 3-1 Month Momentum % is N/A%. Based on the distribution chart, Altamira Therapeutics ranks #1014 out of 1378 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Altamira Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Altamira Therapeutics' 3-1 Month Momentum % compare to CPMV and LYRA?
According to the Biotechnology industry distribution chart, Altamira Therapeutics ranks #1014 out of 1378 companies for 3-1 Month Momentum %. This places Altamira Therapeutics in the lower half of its industry. The industry median 3-1 Month Momentum % is 1.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
The median 3-1 Month Momentum % among Biotechnology companies is 1.51, based on 1,378 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Altamira Therapeutics and its competitors. For the Biotechnology industry, the median 3-1 Month Momentum % is 1.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Altamira Therapeutics's current 3-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Altamira Therapeutics stock overvalued right now?
Altamira Therapeutics (FRA:2QA) has a current 3-1 Month Momentum % of N/A%. The current 3-1 Month Momentum % is N/A%. Altamira Therapeutics' overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Altamira Therapeutics (FRA:2QA), the current 3-1 Month Momentum % is N/A% as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Altamira Therapeutics Ltd is developing and supplying peptide-based nanoparticles for safe and effective RNA delivery to extrahepatic tissues (xPhore platform). The Company is offering biopharmaceutical companies access to its technology for use with their own RNA molecules under collaboration and licensing agreements. The xPhore platform is suitable for various RNA modalities - OligoPhore for oligonucleotides, SemaPhore for mRNA, CycloPhore for circRNA - as well as for DNA (GenePhore). In addition, Altamira Therapeutics is pursuing two proprietary flagship development programs using OligoPhore: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. Geographically, the companies operates in United Staes and Switzerland.
30GF Score
Get the complete analysis for FRA:2QA
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2QA has been successfully added to your 
